Efficacy of Synthetic Bone Graft for Treatment of Peri-implantitis



Status:Recruiting
Healthy:No
Age Range:21 - Any
Updated:11/21/2018
Start Date:November 12, 2018
End Date:March 2020
Contact:Lorenzo Mordini, DDS
Email:LorenzoMordini@creighton.edu
Phone:402-280-5085

Use our guide to learn which trials are right for you!

Clinical Efficacy of Easy-graft CLASSIC for the Treatment of Peri-implantitis

Single arm study to evaluate the effectiveness of treatment approach using a new moldable
beta-tricalcium phosphate(TCP) bone graft material and polylactide membrane in
peri-implantitis.


Inclusion Criteria:

- Subject has read and signed the Institutional Review Board approved consent form
before treatment.

- Subject must be age 21 or above.

- Subject must be willing and able to follow study procedures and instructions.

- Subject affected by moderate to severe peri-implant disease.

- Treated chronic periodontitis and proper periodontal maintenance care.

- Dental implant must meet the following criteria to be selected for the study:

1. Implant presenting Probing Depth ≥ 6 mm

2. Radiographic implant bone loss more than 25% of the implant length (Apex of the
implant to implant platform) .

3. Peri implant bone defect being a buccal dehiscence and semicircular bone
resorption to the middle of the implant body, buccal dehiscence and circular bone
resorption with lingual bone plate intact or circular bone resorption with buccal
and lingual bone plates intact

4. Single tooth implant restoration or implant supported fixed partial denture.

Exclusion Criteria:

- Subjects participating (currently or within 30 days prior to enrollment) in other
clinical trials involving therapeutic intervention (either medical or dental).

- Subjects with poor oral hygiene as indicated by a score of greater than 50% on the
O'Leary Plaque Index.

- Subjects with a systemic condition, which would preclude periodontal treatment,
including but not limited to uncontrolled diabetes.

- Subjects with acute infectious lesions in the areas intended for treatment.

- Subjects taking chronic (i.e., > 2 weeks), therapeutic doses of medications known to
affect bone metabolism such as nonsteroidal anti-inflammatory drugs or
bisphosphonates. Prophylactic aspirin (≤ 325 mg q.d.) for cardiovascular indications
will be permitted in subjects.

- Female subjects who are pregnant or lactating, or sexually-active female subjects who
are of childbearing potential and are not using hormonal or barrier methods of birth
control. (except for when a result of pregnancy test is negative)

- Subjects who are on any chronic antibiotic or steroidal therapy.

- Smoker using more than 10 cigarettes or equivalent per day.

- Smoker using cigar, smokeless tobacco use or e-cigarette.

- Subjects diagnosed with drug induced gingival hyperplasia (e.g. calcium channel
blockers).

- Subjects with radiographic evidence of pathology in other areas of the mouth besides
implant area to be treated.

- Implant mobility.

- Subjects with parafunctional habits and not wearing bite guard.
We found this trial at
1
site
2500 California Plaza
Omaha, Nebraska 68178
Phone: 402-280-5085
?
mi
from
Omaha, NE
Click here to add this to my saved trials